Sunitinib - CAS 557795-19-4
Catalog number: B0084-186154
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
Canonical SMILES:
1.Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J1,2, Kluger H2, Devine L3, Lee JJ4, Kelly WK5, Rink L2, Saif MW6. Cancer Chemother Pharmacol. 2016 Apr 21. [Epub ahead of print]
PURPOSE: Sirolimus, an oral mTOR inhibitor, may complement the anti-angiogenic and anti-tumor activity of sunitinib, an oral small molecule inhibitor of multiple receptor tyrosine kinases, by vertical disruption of vascular epithelial growth factor receptor (VEGFR) signaling, by reducing the compensatory production of VEGF in sunitinib-treated patients and also by directly inhibiting tumor cell proliferation. We conducted this phase 1 study to investigate the maximum tolerated dose (MTD) for this combination of sunitinib and sirolimus in humans.
2.Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C1, Daryani VM2, Billups CA3, Boyett JM3, Leary S4, Tanos R1, Goldsmith KC1, Stewart CF2, Blaney SM5, Gajjar A6. Cancer Med. 2016 Apr 25. doi: 10.1002/cam4.713. [Epub ahead of print]
Sunitinib malate is a small multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor (KIT), which are highly expressed by some high-grade brain tumors. We conducted a phase II study to estimate the efficacy and further characterize the pharmacokinetics of sunitinib in pediatric patients with recurrent or refractory high-grade glioma (Stratum A) or ependymoma (Stratum B). This was a prospective, multicenter Phase II trial conducted through the Children's Oncology Group ( Identifier NCT01462695). Sunitinib, 15 mg/m2, was orally administered once daily for 4 weeks every 6 weeks. The safety and tolerability of sunitinib, an estimate of progression-free survival (PFS), analyses of sunitinib pharmacokinetics (PK) and pharmacodynamics modulation of plasma VEGF and VEGFR2 were also assessed. Thirty eligible patients (17 patients on Stratum A, 13 patients on Stratum B) were enrolled and 29 patients were evaluable for response.
3.Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.
Qu L1, Ding J2, Chen C3, Wu ZJ1, Liu B1, Gao Y1, Chen W1, Liu F4, Sun W2, Li XF2, Wang X2, Wang Y5, Xu ZY5, Gao L6, Yang Q7, Xu B7, Li YM7, Fang ZY7, Xu ZP1, Bao Y1, Wu DS1, Miao X8, Sun HY9, Sun YH7, Wang HY10, Wang LH11. Cancer Cell. 2016 Apr 21. pii: S1535-6108(16)30086-1. doi: 10.1016/j.ccell.2016.03.004. [Epub ahead of print]
Sunitinib resistance is a major challenge for advanced renal cell carcinoma (RCC). Understanding the underlying mechanisms and developing effective strategies against sunitinib resistance are highly desired in the clinic. Here we identified an lncRNA, named lncARSR (lncRNA Activated in RCC with Sunitinib Resistance), which correlated with clinically poor sunitinib response. lncARSR promoted sunitinib resistance via competitively binding miR-34/miR-449 to facilitate AXL and c-MET expression in RCC cells. Furthermore, bioactive lncARSR could be incorporated into exosomes and transmitted to sensitive cells, thus disseminating sunitinib resistance. Treatment of sunitinib-resistant RCC with locked nucleic acids targeting lncARSR or an AXL/c-MET inhibitor restored sunitinib response. Therefore, lncARSR may serve as a predictor and a potential therapeutic target for sunitinib resistance.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related IGF-1R Products

CAS 468740-43-4 BMS-536924

(CAS: 468740-43-4)

BMS-536924 is a potent small molecule inhibitor of IGF-IR, which shows antitumor activity in multiple tumor models, including sarcoma.

CAS 475488-23-4 ADW742

(CAS: 475488-23-4)

NVP-ADW742 is a novel small weight molecular inhibitor of IGF-IR with potential anticancer activity. NVP-ADW742 inhibited IGF-IR-mediated proliferation with an...

CAS 497839-62-0 AEE-788

(CAS: 497839-62-0)

AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth facto...

CAS 6170-42-9 Chloropyramine hydrochloride

Chloropyramine hydrochloride
(CAS: 6170-42-9)

Chloropyramine hydrochloride

CAS 193001-14-8 ZM323881

(CAS: 193001-14-8)

ZM323881 inhibits VEGF-A, EGF and bFEF induced HUVEC cell proliferation with IC50 of 8 nM, 1.9 μM and 1.6 μM, respectively. ZM323881 (10 nM) abolishes VEGF-A-me...

CAS 1054315-48-8 BMS695735

(CAS: 1054315-48-8)

BMS695735 is a benzimidazole inhibitor of the insulin-like growth factor-1 receptor. It was also found to have potent CYP3A4 inhibition. It has broad spectrum i...

(CAS: 1194506-26-7)

Fruquintinib, also known as HMPL-013, is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential ...

CAS 374620-70-9 NBI 31772

NBI 31772
(CAS: 374620-70-9)

NBI-31772 is an insulin-like growth factor-1 binding protein inhibitor. It increases cardiomyocyte proliferation in vivo.

CAS 196868-63-0 PQ 401

PQ 401
(CAS: 196868-63-0)

PQ 401 is an IGF-1R inhibitor and inhibits autophosphorylation of the IGF-IR kinase domain at concentrations <100 nM, with an IC50 <1μM.

CAS 1001350-96-4 BMS-754807

(CAS: 1001350-96-4)

BMS-754807 is an orally bioavailable antagonist of human insulin-like growth factor type I receptor (IGF-1R) with potential antineoplastic activity. BMS-7548077...

CAS 1058137-23-7 Lucitanib

(CAS: 1058137-23-7)

Lucitanib, also known as E-3810, is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor re...

CAS 557795-19-4 Sunitinib

(CAS: 557795-19-4)

Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

(CAS: 638216-89-4)

AG28262 is a bio-active chemical compound. It is a VEFG-r2 inhibitor and could cause an increase in serum ALT, due in part to both gene up-regulation.

E 3810 dihydrochloride

E 3810 dihydrochloride is a dual VEGFR/FGFR tyrosine kinase inhibitor. It suppresses the tumor angiogenesis and tumor cell proliferation via inhibiting VEGFR1, ...

CAS 338992-53-3 Vandetanib trifluoroacetate

Vandetanib trifluoroacetate
(CAS: 338992-53-3)

Vandetanib is an anti-cancer drug that is used for the treatment of certain tumours of thethyroid gland. It acts as a kinase inhibitor of a number of cell recep...

CAS 300842-64-2 NVP-ACC789

(CAS: 300842-64-2)

NVP-ACC789 is a potent, selective and orally active inhibitor of the VEGF receptor tyrosine kinases, antagonizing tumor-driven angiogenesis

CAS 1227939-82-3 Ilorasertib

(CAS: 1227939-82-3)

Ilorasertib, also know as ABT-348, is a novel, potent and orally bioavailable inhibitor of the Aurora kinases as well as the VEGF and PDGF families of receptor ...

CAS 849217-68-1 Cabozantinib

(CAS: 849217-68-1)

Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 1...

Anlotinib Dihydrochloride
(CAS: 1360460-82-7)

Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenic activities, which was designed to ...

CAS 1089283-49-7 GSK-1904529a

(CAS: 1089283-49-7)

GSK-1904529A is an IGF-1R Inhibitor, is is a promising candidate for therapeutic use in IGF-IR–dependent tumors. GSK1904529A selectively inhibits IGF-IR and I...

Chemical Structure

CAS 557795-19-4 Sunitinib

Quick Inquiry

Verification code

Featured Items